Literature DB >> 22895898

Novel C-1 substituted cocaine analogs unlike cocaine or benztropine.

Maarten E A Reith1, Solav Ali, Audrey Hashim, Imran S Sheikh, Naresh Theddu, Narendra V Gaddiraju, Suneet Mehrotra, Kyle C Schmitt, Thomas F Murray, Henry Sershen, Ellen M Unterwald, Franklin A Davis.   

Abstract

Despite a wealth of information on cocaine-like compounds, there is no information on cocaine analogs with substitutions at C-1. Here, we report on (R)-(-)-cocaine analogs with various C-1 substituents: methyl (2), ethyl (3), n-propyl (4), n-pentyl (5), and phenyl (6). Analog 2 was equipotent to cocaine as an inhibitor of the dopamine transporter (DAT), whereas 3 and 6 were 3- and 10-fold more potent, respectively. None of the analogs, however, stimulated mouse locomotor activity, in contrast to cocaine. Pharmacokinetic assays showed compound 2 occupied mouse brain rapidly, as cocaine itself; moreover, 2 and 6 were behaviorally active in mice in the forced-swim test model of depression and the conditioned place preference test. Analog 2 was a weaker inhibitor of voltage-dependent Na+ channels than cocaine, although 6 was more potent than cocaine, highlighting the need to assay future C-1 analogs for this activity. Receptorome screening indicated few significant binding targets other than the monoamine transporters. Benztropine-like "atypical" DAT inhibitors are known to display reduced cocaine-like locomotor stimulation, presumably by their propensity to interact with an inward-facing transporter conformation. However, 2 and 6, like cocaine, but unlike benztropine, exhibited preferential interaction with an outward-facing conformation upon docking in our DAT homology model. In summary, C-1 cocaine analogs are not cocaine-like in that they are not stimulatory in vivo. However, they are not benztropine-like in binding mechanism and seem to interact with the DAT similarly to cocaine. The present data warrant further consideration of these novel cocaine analogs for antidepressant or cocaine substitution potential.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22895898      PMCID: PMC3477221          DOI: 10.1124/jpet.112.193771

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  56 in total

Review 1.  Conditioned place preference: what does it add to our preclinical understanding of drug reward?

Authors:  M T Bardo; R A Bevins
Journal:  Psychopharmacology (Berl)       Date:  2000-12       Impact factor: 4.530

2.  Effects of N-substituted analogs of benztropine: diminished cocaine-like effects in dopamine transporter ligands.

Authors:  Jonathan L Katz; Theresa A Kopajtic; Gregory E Agoston; Amy Hauck Newman
Journal:  J Pharmacol Exp Ther       Date:  2004-01-30       Impact factor: 4.030

3.  Novel N-substituted 3 alpha-[bis(4'-fluorophenyl)methoxy]tropane analogues: selective ligands for the dopamine transporter.

Authors:  G E Agoston; J H Wu; S Izenwasser; C George; J Katz; R H Kline; A H Newman
Journal:  J Med Chem       Date:  1997-12-19       Impact factor: 7.446

4.  Structural requirements for cocaine congeners to interact with dopamine and serotonin uptake sites in mouse brain and to induce stereotyped behavior.

Authors:  M E Reith; B E Meisler; H Sershen; A Lajtha
Journal:  Biochem Pharmacol       Date:  1986-04-01       Impact factor: 5.858

5.  Pharmacological profile of radioligand binding to the norepinephrine transporter: instances of poor indication of functional activity.

Authors:  Maarten E A Reith; Lijuan C Wang; Aloke K Dutta
Journal:  J Neurosci Methods       Date:  2005-04-15       Impact factor: 2.390

6.  Decreases in cocaine self-administration with dual inhibition of the dopamine transporter and σ receptors.

Authors:  Takato Hiranita; Paul L Soto; Stephen J Kohut; Theresa Kopajtic; Jianjing Cao; Amy H Newman; Gianluigi Tanda; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2011-08-22       Impact factor: 4.030

7.  N-substituted benztropine analogs: selective dopamine transporter ligands with a fast onset of action and minimal cocaine-like behavioral effects.

Authors:  Su-Min Li; Theresa A Kopajtic; Matthew J O'Callaghan; Gregory E Agoston; Jianjing Cao; Amy Hauck Newman; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2010-11-18       Impact factor: 4.030

8.  Modification of behavioral effects of cocaine by selective serotonin and dopamine uptake inhibitors in squirrel monkeys.

Authors:  R D Spealman
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

9.  Interaction of cocaine-, benztropine-, and GBR12909-like compounds with wild-type and mutant human dopamine transporters: molecular features that differentially determine antagonist-binding properties.

Authors:  Kyle C Schmitt; Juan Zhen; Prashant Kharkar; Manoj Mishra; Nianhang Chen; Aloke K Dutta; Maarten E A Reith
Journal:  J Neurochem       Date:  2008-09-11       Impact factor: 5.372

10.  Mutation of Trp84 and Asp313 of the dopamine transporter reveals similar mode of binding interaction for GBR12909 and benztropine as opposed to cocaine.

Authors:  Nianhang Chen; Juan Zhen; Maarten E A Reith
Journal:  J Neurochem       Date:  2004-05       Impact factor: 5.372

View more
  11 in total

1.  σ Receptor Effects of N-Substituted Benztropine Analogs: Implications for Antagonism of Cocaine Self-Administration.

Authors:  Takato Hiranita; Weimin C Hong; Theresa Kopajtic; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2017-04-25       Impact factor: 4.030

2.  Structure-Activity Relationship Studies on a Series of 3α-[Bis(4-fluorophenyl)methoxy]tropanes and 3α-[Bis(4-fluorophenyl)methylamino]tropanes As Novel Atypical Dopamine Transporter (DAT) Inhibitors for the Treatment of Cocaine Use Disorders.

Authors:  Mu-Fa Zou; Jianjing Cao; Ara M Abramyan; Theresa Kopajtic; Claudio Zanettini; Daryl A Guthrie; Rana Rais; Barbara S Slusher; Lei Shi; Claus J Loland; Amy Hauck Newman
Journal:  J Med Chem       Date:  2017-12-11       Impact factor: 7.446

Review 3.  Model systems for analysis of dopamine transporter function and regulation.

Authors:  Moriah J Hovde; Garret H Larson; Roxanne A Vaughan; James D Foster
Journal:  Neurochem Int       Date:  2018-09-01       Impact factor: 3.921

Review 4.  Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter.

Authors:  Maarten E A Reith; Bruce E Blough; Weimin C Hong; Kymry T Jones; Kyle C Schmitt; Michael H Baumann; John S Partilla; Richard B Rothman; Jonathan L Katz
Journal:  Drug Alcohol Depend       Date:  2014-12-18       Impact factor: 4.492

5.  Structural basis of GABA reuptake inhibition.

Authors:  Zenia Motiwala; Nanda Gowtham Aduri; Hamidreza Shaye; Gye Won Han; Jordy Homing Lam; Vsevolod Katritch; Vadim Cherezov; Cornelius Gati
Journal:  Nature       Date:  2022-06-08       Impact factor: 69.504

6.  Long-term effects of chronic nicotine on emotional and cognitive behaviors and hippocampus cell morphology in mice: comparisons of adult and adolescent nicotine exposure.

Authors:  Erica D Holliday; Paul Nucero; Munir G Kutlu; Chicora Oliver; Krista L Connelly; Thomas J Gould; Ellen M Unterwald
Journal:  Eur J Neurosci       Date:  2016-10-19       Impact factor: 3.386

7.  Relations between stimulation of mesolimbic dopamine and place conditioning in rats produced by cocaine or drugs that are tolerant to dopamine transporter conformational change.

Authors:  Gianluigi Tanda; Su Min Li; Maddalena Mereu; Alexandra M Thomas; Aaron L Ebbs; Lauren E Chun; Valeria Tronci; Jennifer L Green; Mu-Fa Zou; Theresa A Kopajtic; Amy Hauck Newman; Jonathan L Katz
Journal:  Psychopharmacology (Berl)       Date:  2013-04-24       Impact factor: 4.530

8.  Specific calpain inhibition by calpastatin prevents tauopathy and neurodegeneration and restores normal lifespan in tau P301L mice.

Authors:  Mala V Rao; Mary Kate McBrayer; Jabbar Campbell; Asok Kumar; Audrey Hashim; Henry Sershen; Philip H Stavrides; Masuo Ohno; Michael Hutton; Ralph A Nixon
Journal:  J Neurosci       Date:  2014-07-09       Impact factor: 6.167

9.  Tamoxifen Directly Interacts with the Dopamine Transporter.

Authors:  Sarah R Mikelman; Bipasha Guptaroy; Kyle C Schmitt; Kymry T Jones; Juan Zhen; Maarten E A Reith; Margaret E Gnegy
Journal:  J Pharmacol Exp Ther       Date:  2018-08-14       Impact factor: 4.030

10.  Pharmacological and behavioral characterization of D-473, an orally active triple reuptake inhibitor targeting dopamine, serotonin and norepinephrine transporters.

Authors:  Aloke K Dutta; Soumava Santra; Horrick Sharma; Chandrashekhar Voshavar; Liping Xu; Omar Mabrouk; Tamara Antonio; Maarten E A Reith
Journal:  PLoS One       Date:  2014-11-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.